ABSTRACT
Objective • To investigate the effects of liraglutide on glucose induced expression of miRNA-146b-3p, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2) in human umbilical vein endothelial cells (HUVECs). Methods • HUVECs were grown in the medium with glucose of high concentration (25 mmol/L) or normal concentration (7 mmol/L) for 24 h, then stimulated with liraglutide. Quantitative polymerase chain reaction (qPCR) was performed to detect the expression of miR-146b-3p, IL-6, TNF-α and COX-2. The expression of IL-6, TNF-α and COX-2 were detected after HUVECs were transfected with anti-miR-146b-3p. Results • The expression of miR-146b-3p was decreased in high glucose induced cells, while the expression of IL-6, TNF-α and COX-2 were increased. Silenced expression of miR-146b-3p increased the expression of IL-6, TNF-α and COX-2. Liraglutide increased the expression of miR-146b-3p and decreased the expression of IL-6, TNF-α and COX-2 in high glucose induced cells. Conclusion • Liraglutide may relieve inflammation and improve vascular endothelial function in hyperglycemia condition through regulating miR-146b-3p to decrease expression of IL-6, TNF-α and COX-2.